http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2011151667-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2cd880767c906107e7ec49c31705b1b5 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K33-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K33-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-721 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0014 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0034 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-724 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-24 |
| filingDate | 2010-06-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e937fad39bc4919bbf83890f6d71e398 |
| publicationDate | 2011-12-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2011151667-A1 |
| titleOfInvention | Antiviral compositions |
| abstract | The present invention relates to antimicrobial compositions. Antiviral composition is characterized in that the titanium dioxide, silicon dioxide or barium sulfate nanoparticles sized to max. 200 nm, (2-hydroxy)propyl beta-cyclodextrin (HPBCD) aqueous solution, an excipient selected from a group containing sodium polyacrylate, methylcellulose, ethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, sodium carboxymethylcellulose, poloxamer and auxiliary additives selected from a group containing glycerol, propylene glycol in following per cent ratio: Titanium dioxide or silicon dioxide or barium sulfate 0.05-5.0, HPBCD - 0.05-50, Excipient -0.1-20, Glycerol - 10-20, Purified water - up to 100. Antiviral composition is characterized in that the titanium dioxide, silicon dioxide or barium sulfate nanoparticles sized to max. 200 nm, (2-hydroxy)propyl beta-cyclodextrin (HPBCD) aqueous solution, an excipient selected from a group containing sodium polyacrylate, methylcellulose, ethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, sodium carboxymethylcellulose, poloxamer, auxiliary additives selected from a group containing glycerol, propylene glycol, and paraffin oil in following per cent ratio: Titanium dioxide or silicon dioxide or barium sulfate - 0.05-5.0, HPBCD - 0.05-50, Excipient -0.1-20, Glycerol -10-20, Paraffin oil -1.0-2.0, Purified water - up to 100. Antiviral composition is characterized in that the titanium dioxide, silicon dioxide or barium sulfate nanoparticles sized to max. 200 nm, (2-hydroxy)propyl beta-cyclodextrin (HPBCD) aqueous solution, an excipient of polymeric origin selected from a group containing natural Sodium deoxyribonucleate (DNA) or gelatin and auxiliary additives selected from a group containing glycerol, propylene glycol in following per cent ratio: Titanium dioxide or silicon dioxide or barium sulfate -0.05-5.0, HPBCD -0.05-50, polymeric excipient -0.01-20, Glycerol -10-20, Purified water -up to 100. Nanocomposite formulations under the present invention reduce viral infections by a factor of 100, in vitro. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-4121417-A4 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021180742-A1 |
| priorityDate | 2010-06-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 47.